CytomX: CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
Read full article »
CytomX is an early-stage biotechnology company that develops antibody based therapeutics for the treatment of cancer and inflammatory diseases.
Read more